

John H. Rex, MD is Senior Vice President and Head of Infection, Global Medicines Development at AstraZeneca Pharmaceuticals. Since September 2012, Dr. Rex has also been a Non-Executive (Independent) Director, F2G, Ltd. Based in Manchester, UK, F2G Ltd is dedicated to discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. Through his work at AZ and F2G, Dr. Rex and his colleagues have antibacterial and antifungal molecules in all phases of development from Phase I through registration and marketing.

During his time in Industry, Dr. Rex has led multiple Industry interactions with FDA, EMA, and other external groups with a focus on enhancing available development pathways and the approaches to value for antimicrobial agents. His key activities have included lead authorship of a publication describing an updated approach to regulatory paradigms for antibacterial agents,¹ co-authorship of other publications on the challenge of antimicrobial resistance,^{2,3} founding and ongoing participation in creation and implementation of the New Drugs For Bad Bugs (ND4BB) program within the Innovative Medicines Initiative (IMI) in Europe (including founding participation in the design of DRIVE-AB, a new ND4BB topic focused on evaluation and implementation of novel business models for antibiotics), a 4-year term as Industry Representative on the FDA Anti-Infective Drugs Advisory Committee (AIDAC, 2007-2011), ongoing active leadership within the antimicrobial working groups for EFPIA and PhRMA, ongoing roles (currently Vice-Chair of the Area Committee on Microbiology) with the Clinical Laboratory Standards Institutes (CLSI), membership in the Brookings Council on Antimicrobial Drug Development, and (2014) a role as an advisor on Antimicrobial Resistance to PCAST, the President's Council of Advisors on Science and Technology.

Dr. Rex is also a Highlights Advisor for *Nature Reviews Microbiology*, is a member of the Wellcome Trust Seeding Drug Discovery Committee, serves on several editorial boards, was formerly an Editor for *Antimicrobial Agents and Chemotherapy*, and is an Emeritus Editor for www.doctorfungus.org, a non-profit web site devoted to dissemination of information about medical mycology.

Dr. Rex has an MD from Baylor College of Medicine and is board-certified in Internal Medicine and Infectious Diseases. Before moving to Industry in 2003, Dr. Rex was Professor of Medicine at UT Medical School-Houston with a focus on translational studies of novel antifungal agents and hospital epidemiology.

¹Rex JH et al. Proposal for a comprehensive regulatory framework to address the unmet need for new antibacterial therapies. *The Lancet Infectious Diseases* 13 (3):269 - 275, 2013.

²Spellberg B et al. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. *Clin Infect Dis* 52(S5):S397–S428, 2011.

³Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. *Nature Rev Drug Disc* 11:168-70, 2012.